MoonLake Immunotherapeutics MLTX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$230.32M-90.0% | -$121.24M-175% | -$44.08M+14.1% | -$51.33M+8.3% | ||
| $2.62M+88.9% | $1.39M+274% | $370K+125% | $164.78K— | ||
| $12.9M+77.1% | $7.28M+2.5% | $7.11M-26.4% | $9.65M— | ||
| $20.56M— | —— | —— | —— | ||
| —— | $5.17M— | —— | $2.69M-63.4% | ||
| —— | $0— | $0— | —— | ||
| —— | $247K+282% | -$135.43K-97.8% | -$68.45K— | ||
| -$561K— | —— | $6.35M— | —— | ||
| -$58K-5,900% | $1K+101% | -$85K-128% | $304.03K— | ||
| -$1.22M+14.1% | -$1.42M-541% | -$222K-45.6% | -$152.43K— | ||
| $2.03M+13.4% | $1.79M+113% | $840K— | —— | ||
| -$196.01M-68.1% | -$116.59M-173% | -$42.78M+23.5% | -$55.89M+11.1% | ||
| —— | $520K+83.1% | $284K— | —— | ||
| $265.37M-24.2% | $350.28M+99.3% | $175.73M+316% | $42.23M— | ||
| $468.4M— | —— | $150.83M+1,423% | $9.9M— | ||
| —— | —— | —— | —— | ||
| —— | $0— | —— | —— | ||
| —— | —— | $0— | $0— | ||
| $146M+185% | $51.31M-89.3% | $479.7M+301% | $119.69M+67.3% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $5.06M— | —— | $0— | —— | ||
| —— | $5.17M— | —— | $2.69M-63.4% | ||
| -$1.22M+14.1% | -$1.42M-541% | -$222K-45.6% | -$152.43K— | ||
| $0— | —— | $66K— | $0— | ||
| $2.03M+13.4% | $1.79M+113% | $840K— | —— | ||
| -$561K— | —— | $6.35M— | —— | ||
| —— | $247K+282% | -$135.43K-97.8% | -$68.45K— | ||
| -$58K-5,900% | $1K+101% | -$85K-128% | $304.03K— | ||
| $468.4M— | —— | $150.83M+1,423% | $9.9M— | ||
| —— | —— | —— | —— | ||
| -$1.22M+14.1% | -$1.42M-541% | -$222K-45.6% | -$152.43K— | ||
| $0— | —— | $3.64M+736% | $435.01K— | ||
| -$196.04M-67.4% | -$117.11M-172% | -$43.06M+23.0% | -$55.91M— | ||
| -$196.04M-67.4% | -$117.11M-172% | -$43.06M+23.0% | -$55.91M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does MoonLake Immunotherapeutics generate?
- MoonLake Immunotherapeutics (MLTX) generated -$224.2M in operating cash flow over the trailing twelve months.
- What is MoonLake Immunotherapeutics's free cash flow?
- After $343.0K of capital expenditures, MoonLake Immunotherapeutics's free cash flow was -$224.2M over the trailing twelve months, down 60.0% year over year.
- Where does MoonLake Immunotherapeutics's cash flow data come from?
- Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.